Prescription trends for obesity medications surge, tied to growing interest in GLP-1 drugs

Prescription trends for obesity medications surge, tied to growing interest in GLP-1 drugs

Source: News-Medical.Net

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest influences prescription trends.

Monthly prescriptions for obesity medications reached 1.5 million in February 2024, with semaglutide (Wegovy) and tirzepatide (Zepbound) gaining market share as phentermine’s dominance declines
A recent study published in JAMA Network Open finds a st… [6047 chars]

Read more